Original from: genomeweb Illumina and Macrogen announced on Monday that they are collaborating to sequence and analyze 145,952 genomes as part of South Korea's National Bio Big Data project. ..

On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promo..

Original from: business wire Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in develo..

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into a comprehensive strategic agreement with Graves Gilbert Clinic to manage the lab operations of its main full-service laboratory in Bowling Green, Kentucky, and its location in Glasgow, Kentucky.

2.4 Pertussis Diagnosis Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics. In recent years, the incidence of pertussis in children has increas..

Ovation.io, Inc., an organization dedicated to building best in class multi-omics datasets, today announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that will work to accelerate advancements in precision medicine. The collaboration will address challenges in drug development by harnessing the power of genomic data to enable the discovery of drug targets coupled with biomarkers that increase the probability of success and decrease the cost of development.

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.

Sansure Biotech’s Monkeypox virus nucleic acid testing kit approved for market launch Recently, the Monkeypox Virus Nucleic Acid Testing Kit (PCR-Fluorescent Probe Method) independently developed by San..

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network.

Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.

From December 14 to 18, a delegation led by Lei Haichao, Director of China's National Health Commission, visited Japan to attend the 17th Tripartite Health Ministers’ Meeting and engage in a series of official activities

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer.

OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC).

Original from: 360dx The Davos Alzheimer's Collaborative (DAC) announced on Wednesday that it is partnering with Janssen Research & Development and Danaher subsidiary Beckman Coulter Diagnostics to v..